Join the Paxlovid group to help and get support from people like you.
Paxlovid News
Nirmatrelvir-Ritonavir Does Not Speed Up Alleviation of COVID-19 Symptoms
FRIDAY, April 5, 2024 – For patients with confirmed COVID-19, nirmatrelvir-ritonavir is not associated with a shorter time to sustained alleviation of symptoms than placebo, according to a study...
COVID-19 Viral Load Rebound Can Occur After VV116, Nirmatrelvir-Ritonavir
WEDNESDAY, March 20, 2024 – For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116 or...
Paxlovid Won't Cut Odds for Long COVID: Study
MONDAY, Jan. 8, 2024 – Paxlovid might help shorten and diminish a COVID infection, but the antiviral doesn’t reduce the risk of developing long COVID, a new study shows. About 16% of COVID patients t...
Nirmatrelvir During Acute SARS-CoV-2 Does Not Reduce Risk for Long COVID
FRIDAY, Jan. 5, 2024 – Treatment with nirmatrelvir during acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not associated with a reduced risk for subsequent...
SARS-CoV-2 Rebound Rate Similar With, Without Oral Antivirals
FRIDAY, Dec. 22, 2023 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound occurs at a similar rate for those receiving and not receiving oral antiviral treatment and for those...
COVID Rebound Occurs in 1 in 5 People Taking Paxlovid
TUESDAY, Nov. 14, 2023 – Paxlovid helps prevent severe COVID-19, but it also might significantly increase a person’s risk of a rebound case, a new study confirms. About 1 in 5 people taking Paxlovid ...
Virologic Rebound Occurs in ~20 Percent Receiving Nirmatrelvir-Ritonavir
TUESDAY, Nov. 14, 2023 – For patients receiving nirmatrelvir-ritonavir (N-R) for acute COVID-19, virologic rebound (VR) occurs in about one in five, according to a study published online Nov. 14 in...
Paxlovid Probably Won't Your Cut Odds for Long COVID: Study
TUESDAY, Oct. 31, 2023 – The antiviral drug Paxlovid is great at treating COVID-19 infections, but a new study casts doubt on its effectiveness at preventing symptoms associated with long COVID....
Paxlovid Not Helpful for Reducing Most Post-COVID-19 Conditions
TUESDAY, Oct. 31, 2023 – Outpatient treatment of COVID-19 with nirmatrelvir-ritonavir (Paxlovid) reduces the risk for combined thromboembolic events, but does not affect the risk for other...
Paxlovid and Other COVID-19 Meds Will Soon Have Big Price Tags
MONDAY, Oct. 30, 2023 – Americans have been getting COVID-19 treatments such as Paxlovid for free, but that is about to end. The medications will enter the private market this week, the Associated...
COVID Meds Like Paxlovid Will Soon Have Big Price Tags
MONDAY, Oct. 30, 2023 – Americans have been getting COVID treatments such as Paxlovid for free, but that’s about to end. The medications will enter the private market this week, the Associated Press ...
Nirmatrelvir/Ritonavir Cuts COVID-19 Complications in Highest-Risk Patients
WEDNESDAY, Oct. 4, 2023 – For individuals with the highest risk for complications from COVID-19 infection, nirmatrelvir and ritonavir is associated with a reduced risk for COVID-19 hospitalization...
Nirmatrelvir, Molnupiravir Use Lowers Risks for Omicron-Infected
MONDAY, Sept. 25, 2023 – For patients infected with omicron at high risk for progression to severe disease, treatment with nirmatrelvir or molnupiravir is associated with reductions in mortality and...
President Biden Gets COVID, Flu Shots
MONDAY, Sept. 25, 2023 – President Joe Biden has been freshly vaccinated for three major respiratory viruses that could spread widely this fall and winter. Biden got both the updated COVID booster a...
Practice Points Developed for Treatment of Outpatient COVID-19
WEDNESDAY, Sept. 20, 2023 – In an updated clinical guideline issued by the American College of Physicians and published online Sept. 19 in the Annals of Internal Medicine, living, rapid practice...
Ask a question
To post your own question to this support group, sign in or create an account.